{"product_id":"oricpharma-business-model-canvas","title":"ORIC Pharmaceuticals Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the strategic playbook: Business Model Canvas for oncology value creation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock ORIC Pharmaceuticals’s strategic playbook with our Business Model Canvas—three to five concise, actionable sentences map how the company creates value, partners, and captures revenue in oncology and specialty therapeutics. Ideal for investors and strategists, the full Word\/Excel canvas delivers section-by-section analysis and practical insights to guide decisions—download it to benchmark, plan, or pitch with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic oncology centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with leading academic oncology centers provide access to resistant tumor models and translational expertise critical for ORIC’s programs, informing Phase 1\/2 development in 2024. Joint studies accelerate target validation and biomarker discovery, shortening preclinical-to-clinic timelines. These partners enable early clinical trial sites, KOL engagement, and bolster credibility with regulators and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma co-development alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharma co-development alliances let ORIC share late-stage trial risk and access larger firms' resources, with partners supplying commercialization infrastructure and global reach. Co-funding and option structures de-risk pipeline advancement and often fund pivotal studies. Alliances also enable combination studies with partner therapies, accelerating development timelines in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical research organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical research organizations deliver trial operations, monitoring, data management and global site activation, enabling ORIC to run complex oncology studies. CRO partnerships scale multi-center trials efficiently; the global CRO market was roughly $70 billion in 2024, reflecting broad capacity. Robust CRO quality systems underpin regulatory compliance and patient safety. Their extensive geographic footprint accelerates enrollment in niche indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker and diagnostics vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompanion diagnostics partners enable precise patient selection and resistance mechanism tracking, aligning assay development with regulatory co-approval pathways and leveraging FDA guidance; by 2024 there are over 60 cleared\/approved CDx supporting oncology approvals. High-quality bioinformatics increases responder identification accuracy, boosting probability of clinical success and payer acceptance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCDx cleared\/approved: \u0026gt;60 (2024)\u003c\/li\u003e\n\u003cli\u003eRegulatory-aligned assays: co-approval pathway\u003c\/li\u003e\n\u003cli\u003eBioinformatics: improves responder ID, lowers trial risk\u003c\/li\u003e\n\u003cli\u003eOutcome: higher clinical success and payer uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eORIC leverages CDMOs for GMP synthesis, formulation and CMC scalability for small molecules, ensuring clinical-to-launch supply continuity. In 2024 over 60% of small-molecule production was outsourced, supporting global filings via technical transfer and robust quality systems. Cost-efficient CDMO production preserves sustainable gross margins during scale-up.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 CDMO market ≈ $129B\u003c\/li\u003e\n\u003cli\u003e\u0026gt;60% small-molecule outsourcing (2024)\u003c\/li\u003e\n\u003cli\u003eReduced COGS supports margin resilience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnerships de-risk development and scale: academia, pharma, CROs, CDx, CDMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcademic collaborations supply resistant models and translational expertise; pharma alliances share late‑stage risk and commercialization; CROs, CDx and CDMOs provide trial execution, patient selection and GMP supply to de‑risk development and scale launch.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\u003c\/td\u003e\n\u003ctd\u003eTranslational models\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003eCo‑dev\/commercial\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eTrial ops\u003c\/td\u003e\n\u003ctd\u003e$70B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDx\u003c\/td\u003e\n\u003ctd\u003ePatient selection\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60 cleared\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\u003c\/td\u003e\n\u003ctd\u003eGMP supply\u003c\/td\u003e\n\u003ctd\u003e$129B market; \u0026gt;60% outsourcing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for ORIC Pharmaceuticals detailing its oncology-focused value propositions, target customer segments (patients, providers, payers), revenue pathways (partnered licensing, milestone payments, royalty streams) and key activities (R\u0026amp;D, clinical trials, regulatory strategy). Designed for investor presentations, it maps partners, cost structure, channels, and competitive advantages with linked SWOT insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of ORIC Pharmaceuticals’ business model with editable cells, pinpointing R\u0026amp;D bottlenecks, partner dependencies and commercialization pain points for faster decision-making. Great for team workshops, board reviews, or investor briefings to align strategy and action.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTarget discovery and validation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIdentify resistance pathways and druggable targets using genomics and functional CRISPR\/RNAi screens covering ~18,000 genes to pinpoint actionable hits. Validate leads in vitro and in vivo using resistant cell lines and PDX models. Prioritize assets by translational biomarkers and unmet need (eg, cancers with \u0026lt;15% 5-year survival) and build IP around novel mechanisms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLead optimization and CMC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRefine small molecules for potency, selectivity, PK\/PD and safety through iterative medicinal chemistry and in vivo validation, targeting the 2024 industry preclinical-to-IND success range of roughly 10–20%. Develop scalable, stable formulations and validated analytical methods to support GMP manufacturing and consistent batch release. Reduce off-target liabilities early via ADME\/tox screening and in vitro safety pharmacology, and compile robust CMC packages aligned with FDA IND expectations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign biomarker-enriched Phase 1\/2 trials (cohorts typically 20–40 patients) to demonstrate proof-of-concept and enable rapid go\/no-go decisions. Optimize dose, schedule and combination regimens through adaptive designs and PK\/PD modeling. Manage sites, enrollment and centralized safety monitoring to meet projected 12–18 month cohort timelines. Generate high-quality, regulatory-grade datasets for IND\/IMPD and agency interactions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory strategy and engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory strategy focuses on pursuing expedited pathways (Fast Track, Breakthrough) where eligible, driving frequent FDA\/EMA engagements to align on clinical endpoints and companion diagnostics, preparing precise submissions and timely responses, and maintaining rigorous GCP compliance across trials to de-risk development and accelerate approval timelines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpedited pathway targeting: Fast Track\/Breakthrough\u003c\/li\u003e\n\u003cli\u003eFrequent FDA\/EMA alignment on endpoints\/diagnostics\u003c\/li\u003e\n\u003cli\u003ePrecise submissions and rapid responses\u003c\/li\u003e\n\u003cli\u003eStrict GCP compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness development and alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBusiness development and alliances at ORIC Pharmaceuticals focus on sourcing and negotiating partnerships, licenses, and co-development deals with milestone and royalty frameworks tied to value inflection; as of 2024 ORIC Pharmaceuticals (NASDAQ: ORIC) actively pursues regional and indication expansion while coordinating joint governance and IP strategy across collaborators.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSource and negotiate partnerships\u003c\/li\u003e\n\u003cli\u003eMilestones and royalties aligned to inflection\u003c\/li\u003e\n\u003cli\u003eJoint governance and IP coordination\u003c\/li\u003e\n\u003cli\u003eExpand optionality across geographies and indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenomics CRISPR screens (~\u003cstrong\u003e18,000\u003c\/strong\u003e genes) de-risk leads; \u003cstrong\u003e10–20%\u003c\/strong\u003e preclin→IND\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUse genomics and CRISPR\/RNAi screens (~18,000 genes) to find resistance pathways and build IP around validated hits.\u003c\/p\u003e\n\u003cp\u003eAdvance leads via iterative medicinal chemistry, aiming for 10–20% preclinical-to-IND success (2024 benchmarks) with ADME\/Tox and GMP-ready CMC.\u003c\/p\u003e\n\u003cp\u003eRun biomarker-driven Phase 1\/2 cohorts (20–40 pts) with 12–18 month cohort timelines and pursue Fast Track\/Breakthrough interactions (ORIC, NASDAQ: ORIC, active 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenes screened\u003c\/td\u003e\n\u003ctd\u003e~18,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclin→IND\u003c\/td\u003e\n\u003ctd\u003e10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCohort size\u003c\/td\u003e\n\u003ctd\u003e20–40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCohort timeline\u003c\/td\u003e\n\u003ctd\u003e12–18 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document previewed here is the actual ORIC Pharmaceuticals Business Model Canvas, not a mockup or sample. When you purchase, you’ll receive this exact file with all sections included. Delivered ready-to-edit in Word and Excel formats. No surprises—what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology R\u0026amp;D talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExperienced medicinal chemists, biologists, translational scientists and clinicians drive ORIC’s oncology innovation, focusing on resistance mechanisms that underpin program selection. Their domain expertise in resistance biology is central to target validation. Cross-functional teams shorten cycle times—McKinsey 2024 estimates 30–50% faster development. A data-driven culture guides \u0026gt;70% strategic decisions, improving go\/no-go accuracy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary resistance models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProprietary resistance models—custom cell lines, PDXs, and organoids reflecting clinical resistance phenotypes—are differentiating assets for ORIC as of 2024. They enable predictive preclinical testing that improves translational decision-making. Integrated biomarker platforms support patient stratification and trial enrichment. Aggregated datasets compound learning across programs, accelerating candidate selection and de-risking clinical paths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual property portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatents on compounds, compositions and methods form the core of ORIC Pharmaceuticals intellectual property, granting statutory protection with typical patent terms of up to 20 years. Filing strategies extend exclusivity across indications and geographies and can be complemented by regulatory exclusivities of up to five years in many jurisdictions. Trade secrets preserve proprietary assays and analytics, while freedom-to-operate analyses de-risk development and commercialization pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and regulatory relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eORIC Pharmaceuticals leverages established networks with investigators, trial sites, and regulators to accelerate enrollment and trial milestones, with KOL advocacy shaping protocol design and boosting recruitment. Prior interactions with regulators inform adaptive regulatory strategy, improving prospects for expedited pathways; FDA priority review averages 6 months versus 10 months standard in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInvestigator\/site networks: improved enrollment\u003c\/li\u003e\n\u003cli\u003eKOL advocacy: protocol credibility\u003c\/li\u003e\n\u003cli\u003eRegulatory interactions: adaptive strategy\u003c\/li\u003e\n\u003cli\u003eExpedited access: priority review 6m (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital and partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eORIC in 2024 leverages capital and partnerships to extend cash runway via equity access and non-dilutive funding; collaboration payments and milestone-triggered receipts materially offset R\u0026amp;D spend and provide contingent capital.\u003c\/p\u003e\n\u003cp\u003eThis financial flexibility enables portfolio prioritization, reallocating resources to high-value programs while preserving upside for future financing rounds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 emphasis: equity + non-dilutive mix\u003c\/li\u003e\n\u003cli\u003eCollaboration payments offset R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eMilestones = contingent capital\u003c\/li\u003e\n\u003cli\u003eFlexibility supports prioritization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResistance R\u0026amp;D cuts time \u003cstrong\u003e30-50%\u003c\/strong\u003e, \u0026gt; \u003cstrong\u003e70%\u003c\/strong\u003e data-driven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExperienced chemists, biologists and clinicians with resistance-biology focus drive target validation; cross-functional teams cut development time 30–50% (McKinsey 2024). Proprietary resistance models, biomarkers and aggregated datasets improve translational predictivity; \u0026gt;70% strategic decisions are data-driven. Patents, trade secrets and investigator\/regulatory networks support expedited pathways (FDA priority review 6m, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTeams\u003c\/td\u003e\n\u003ctd\u003e30–50% faster\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData-driven\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70% decisions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003ePriority review 6m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinance\u003c\/td\u003e\n\u003ctd\u003eEquity + non-dilutive\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOvercoming treatment resistance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORIC Pharmaceuticals is a clinical-stage company whose programs target mechanisms that limit current oncology therapies to restore or extend efficacy, potentially producing longer durable responses and expanding options for physicians after standard care fails; as of 2024 ORIC advances multiple Phase 1\/2 programs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker-driven precision\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompanion diagnostics focus treatment on likely responders, with over 50 FDA-cleared companion diagnostics as of 2024, driving 2–3x higher response rates in biomarker-selected oncology cohorts, boosting clinical success and payer value; this enables smaller, faster trials (reducing required sample sizes substantially) and yields more predictable real-world outcomes for ORIC’s targeted programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRational combinations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eORIC assets are engineered for use alongside targeted agents and immuno-oncology drugs, addressing a market where over 50% of oncology trials in 2024 test combinations and the global oncology therapeutics market exceeded $200B in 2024; synergistic combinations can delay resistance emergence, combination-ready safety profiles are prioritized to enable co-dosing, and this approach broadens market adoption and payer uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall molecule convenience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSmall-molecule oral dosing improves patient quality of life through simple at-home regimens and higher outpatient adherence; oral drugs represent roughly 90% of marketed small-molecule medicines by count. Manufacturing is scalable and generally lower-cost versus biologics, which accounted for about 30% of global pharma sales in 2023, and distribution is straightforward without complex cold-chain logistics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral dosing: higher outpatient adherence\u003c\/li\u003e\n\u003cli\u003eManufacturing: lower CAPEX and per-dose cost vs biologics\u003c\/li\u003e\n\u003cli\u003eDistribution: no cold chain, easier market roll-out\u003c\/li\u003e\n\u003cli\u003eMarket context: small molecules ~90% by count; biologics ~30% of sales (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData transparency and speed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eORIC Pharmaceuticals in 2024 emphasized clear clinical updates and robust translational science to build stakeholder trust, using adaptive study designs that accelerate go\/no-go decisions and shorten timelines.\u003c\/p\u003e\n\u003cp\u003eEarly biological signals guide capital allocation and program prioritization, demonstrating disciplined execution visible to investors and partners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClear updates: regular 2024 readouts\u003c\/li\u003e\n\u003cli\u003eAdaptive designs: faster decisions\u003c\/li\u003e\n\u003cli\u003eEarly signals: resource focus\u003c\/li\u003e\n\u003cli\u003eStakeholders: visible discipline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeting resistance to extend oncology responses with Phase 1\/2 programs and \u003cstrong\u003e50+\u003c\/strong\u003e FDA-cleared diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eORIC targets resistance mechanisms to restore\/extend oncology efficacy, advancing multiple Phase 1\/2 programs in 2024 to deliver longer durable responses. Companion diagnostics (50+ FDA-cleared in 2024) enable 2–3x higher response rates in biomarker-selected cohorts, shrinking trial sizes and improving success odds. Oral, combination-ready small molecules align with \u0026gt;50% of 2024 oncology trials testing combos and a \u0026gt;$200B 2024 market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical stage\u003c\/td\u003e\n\u003ctd\u003eMultiple Phase 1\/2 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompanion diagnostics\u003c\/td\u003e\n\u003ctd\u003e50+ FDA-cleared (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombo trials\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% testing combos (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral share\u003c\/td\u003e\n\u003ctd\u003e~90% by count\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician education programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEngage oncologists through scientific exchange, CME initiatives and congress presence—ASCO Annual Meeting draws about 40,000 participants, maximizing reach to key opinion leaders. Provide biomarker guidance and clear treatment algorithms aligned with regulatory companion diagnostic labels to drive appropriate patient selection. Support with medical information services and foster peer-to-peer learning networks to accelerate adoption and feedback.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient and advocacy engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborate with advocacy groups to improve trial awareness and access, targeting underserved populations to boost enrollment. Provide plain-language resources on resistance biology and practical therapy support (financial navigation, side-effect management). Address psychosocial and logistical needs during therapy through coordinated services. Integrate patient feedback into development; only about 3–5% of adult cancer patients enroll in trials (2024), so advocacy partnerships expand reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey opinion leader advisory\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdvisory boards of 8–12 key opinion leaders inform study design and endpoints to align trials with regulatory and payer expectations. KOLs commonly accelerate site activation by ~20% and drive publication strategy and authorship networks. Their endorsement builds credibility with investigators and payers, improving enrollment and retention. Ongoing dialogues with KOLs refine clinical positioning across multi‑site programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and HTA dialogue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly health economics modeling informs clear value stories and scenarios for payers and HTAs; align on outcomes that matter and plan RWE and biomarker evidence collection to support coverage decisions in 2024. Share real-world and biomarker data iteratively and prepare template terms for evidence-based contracts where appropriate. Engage HTAs early to agree endpoints and cost-effectiveness thresholds.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly HE modeling supports value dossiers\u003c\/li\u003e\n\u003cli\u003eShare RWE and biomarker datasets\u003c\/li\u003e\n\u003cli\u003eAlign on HTA-priority outcomes\u003c\/li\u003e\n\u003cli\u003ePrepare evidence-based contracting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner co-governance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartner co-governance at ORIC Pharmaceuticals uses joint steering committees to oversee co-development plans, with transparent dashboards tracking clinical and regulatory milestones and financial spend. Issues are resolved through pre-defined decision rights and escalation paths to maintain pace and de-risk timelines. Commercial strategy alignment is preserved via shared KPIs and regular executive reviews.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNASDAQ ticker: ORIC\u003c\/li\u003e\n\u003cli\u003eJoint steering committees\u003c\/li\u003e\n\u003cli\u003eTransparent milestone dashboards\u003c\/li\u003e\n\u003cli\u003eStructured decision rights\u003c\/li\u003e\n\u003cli\u003eShared commercial KPIs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEngage oncologists at ASCO and KOL boards to boost site activation \u003cstrong\u003e~20%\u003c\/strong\u003e and trial enrollment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngage oncologists via CME, ASCO (~40,000 attendees) and KOL advisory boards (8–12 members) to speed site activation ~20% and drive adoption. Provide biomarker-guided algorithms and medical support; only 3–5% of adult cancer patients enroll in trials (2024). Partner with advocacy groups to expand enrollment and provide financial\/side-effect support. Early HE modeling and RWE sharing shape payer agreements.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eASCO attendance\u003c\/td\u003e\n\u003ctd\u003e~40,000 (annual)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial enrollment\u003c\/td\u003e\n\u003ctd\u003e3–5% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKOL board\u003c\/td\u003e\n\u003ctd\u003e8–12 members\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite activation boost\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty oncology sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORIC Pharmaceuticals (NASDAQ: ORIC) will deploy a focused field force to top NCI‑designated centers (71 as of 2024) post‑approval, prioritizing high‑volume hubs. Teams will educate clinicians on biomarkers and patient selection, engage tumor boards and pharmacy leaders, and monitor utilization and real‑time feedback to optimize uptake and access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2024 ORIC Pharmaceuticals leverages established clinical trial networks for faster enrollment and robust data generation, reducing time-to-readout and supporting go\/no-go decisions. Trial visibility seeds future adoption among oncologists and referral centers. Deep site relationships enable post-launch investigator-initiated studies and real-world data capture. Streamlined data flow underpins peer-reviewed publications and regulatory filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical congresses and journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePresent data at ASCO (≈30–40k attendees), ESMO (≈25k) and AACR (≈20k) and publish in peer-reviewed journals to build scientific credibility that drives uptake; peer-reviewed publication increases prescribing adoption by as much as 15–25% in oncology launches. KOL discussions and advisory boards amplify messages across networks of \u0026gt;1,000 specialists. Timed disclosures tied to IND\/phase milestones optimize market impact and investor confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital medical platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital medical platforms deliver HCP portals with protocols, diagnostic guides and safety data; webinars and virtual advisory boards scale expert reach while CRM tracks engagement and identifies education gaps. These channels reinforce patient adherence via digital tools and reminders. As of 2024 ORIC Pharmaceuticals remained a clinical-stage company with no approved products, prioritizing education and KOL engagement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHCP portals: protocols, diagnostics, safety\u003c\/li\u003e\n\u003cli\u003eWebinars\/VABs: scalable KOL reach\u003c\/li\u003e\n\u003cli\u003eCRM: engagement \u0026amp; education gap analytics\u003c\/li\u003e\n\u003cli\u003eDigital tools: adherence support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostics partner channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLeverage CDx partners’ lab networks to identify eligible patients by integrating ORIC assays into labs that collectively handled an estimated $8.2B companion-diagnostic market in 2024, expanding reach into oncology cohorts.\u003c\/p\u003e\n\u003cp\u003eCo-promote testing pathways and streamline ordering\/reporting into clinics via EMR integrations to cut turnaround and increase throughput for biomarker-driven adoption.\u003c\/p\u003e\n\u003cp\u003eHigher throughput accelerates enrollment and commercial uptake, converting lab volume into measurable patient identification and therapy alignment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReach: taps major CDx lab networks (2024 market ~$8.2B)\u003c\/li\u003e\n\u003cli\u003eEfficiency: EMR-integrated ordering\/reporting\u003c\/li\u003e\n\u003cli\u003eScale: higher throughput → faster biomarker adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeting 71 NCI hubs and CDx in an $8.2B 2024 market to accelerate patient ID \u0026amp; EMR orders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eORIC targets 71 NCI centers with a focused field force, prioritizing high‑volume hubs to drive uptake. Leverages CDx lab networks in a $8.2B 2024 market to ID patients and integrate EMR ordering. Scientific channels (ASCO 30–40k, ESMO 25k) plus publications\/KOLs scale adoption and referral flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField force\u003c\/td\u003e\n\u003ctd\u003e71 NCI centers\u003c\/td\u003e\n\u003ctd\u003eTargeted uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDx labs\u003c\/td\u003e\n\u003ctd\u003e$8.2B market\u003c\/td\u003e\n\u003ctd\u003ePatient ID\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003eASCO 30–40k\u003c\/td\u003e\n\u003ctd\u003eCredibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical oncologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical oncologists are primary prescribers in academic and community settings, managing care for patients who fail standard regimens and increasingly seeking targeted options. They value therapies with clear biomarker criteria and manageable safety profiles to guide treatment selection. Practice patterns align with evidence-based guidelines such as NCCN and WHO\/IARC data (over 19.3 million new cancer cases globally in 2020) inform demand for novel options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCancer centers and hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstitutional buyers like ~6,000 US hospitals and 71 NCI-designated cancer centers prioritize outcomes and pathway fit for ~1.9M new cancer cases projected in 2024; P\u0026amp;T committees rigorously assess clinical evidence and budget impact. Access hinges on formulary inclusion and reimbursement decisions, while availability of patient-support and infusion services materially speeds adoption and formulary uptake timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with resistant cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith 1.96 million new US cancer cases estimated in 2024, many patients with progressed, treatment‑resistant disease urgently seek effective later‑line options; oral, tolerable regimens are strongly preferred to preserve quality of life. Access and financial support—manufacturer patient assistance and insurance navigation—are critical, and advocacy groups such as the American Cancer Society play key roles in coordinating care and resources.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and HTA bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers and HTA bodies focus on cost-effectiveness and demand robust biomarker- and outcomes-driven evidence for coverage; real-world evidence increasingly determines contracting and risk-sharing terms, while prior authorization and utilization management shape patient access.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare ≈64 million beneficiaries (2024)\u003c\/li\u003e\n\u003cli\u003eCost-effectiveness central to HTA decisions\u003c\/li\u003e\n\u003cli\u003eRWE tied to outcomes-based contracts\u003c\/li\u003e\n\u003cli\u003ePrior authorization influences uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiopharma partners in 2024 target ORIC for combination synergies or portfolio expansion, pursuing co-development or in-licensing of mechanistically differentiated assets with clear biomarker strategies; they prioritize robust IP estates and demonstrable execution to de-risk collaborations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCombination synergies\u003c\/li\u003e\n\u003cli\u003eCo-development \/ in-licensing\u003c\/li\u003e\n\u003cli\u003eMechanistic differentiation\u003c\/li\u003e\n\u003cli\u003eBiomarker-led value\u003c\/li\u003e\n\u003cli\u003eStrong IP \u0026amp; execution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncologists drive biomarker-led, tolerable later-line care for \u003cstrong\u003e1.96M\u003c\/strong\u003e US cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedical oncologists drive prescribing for 1.96M new US cancer cases (2024), prioritizing biomarker-led, tolerable later-line therapies. Institutions (≈6,000 US hospitals, 71 NCI centers) and P\u0026amp;T committees require robust outcomes and budget impact. Payers (Medicare ≈64M beneficiaries) demand cost-effectiveness, RWE and utilization controls for coverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew US cases\u003c\/td\u003e\n\u003ctd\u003e1.96M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e≈6,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNCI centers\u003c\/td\u003e\n\u003ctd\u003e71\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\u003c\/td\u003e\n\u003ctd\u003e≈64M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical trial spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical trial spend for ORIC centers on preclinical studies, Phase 1\/2 trials and CRO fees, with industry 2024 estimates placing Phase 1 at $1–5M and Phase 2 at $10–40M per trial; CRO contracts and site payments often constitute 30–50% of total trial budgets. Monitoring, clinical data management and central labs drive substantial recurring costs, while biomarker assays add incremental costs typically in the low six figures per study. Adaptive designs are used to improve patient allocation and reduce overall spend and timeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMC and manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcess development, GMP production and quality control are the largest CMC drivers; 2024 benchmarks show CMC can consume 20–30% of pre-IND\/IND budgets. Scale-up and stability studies supporting filings add $1–10M per program. CDMO retainers and tech transfers (often $100k–$500k+) increase fixed costs, while clinical-trial inventory planning typically requires $0.5–5M reserve. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePreparation of INDs\/NDAs and ongoing compliance consume multi‑million dollars—IND\/NDA prep often runs $2–10M and US PDUFA user fee for 2024 was about $3.2M—while audits, pharmacovigilance and safety database maintenance typically cost $0.5–3M annually; consultancy and legal fees can add $0.5–2M; global filings (EU, UK, Japan, China) can multiply total regulatory spend 2–5x.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial readiness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePre-launch medical affairs, market access and education programs typically require $10–50M to build demand; fully loaded US field rep cost is about $200–300k\/year, driving hiring and training spend; companion diagnostic co-development often costs $10–30M; post-marketing studies frequently continue at $5–50M depending on scope.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eprelaunch_budget: $10–50M\u003c\/li\u003e\n\u003cli\u003erep_cost_ann: $200–300k\u003c\/li\u003e\n\u003cli\u003ecompanion_dx: $10–30M\u003c\/li\u003e\n\u003cli\u003epost_marketing: $5–50M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eG\u0026amp;A and IP protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCorporate operations, finance, and HR provide core enterprise support while facilities, IT, and infrastructure create steady overhead; 2024 industry surveys show G\u0026amp;A often absorbs roughly 20–25% of biotech operating budgets. Patent filing, prosecution, and maintenance fees persist throughout program life, and insurance plus governance costs are ongoing line items. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eG\u0026amp;A share: 20–25%\u003c\/li\u003e\n\u003cli\u003eOngoing patent lifecycle costs\u003c\/li\u003e\n\u003cli\u003eFacilities \u0026amp; IT overhead\u003c\/li\u003e\n\u003cli\u003eRecurring insurance \u0026amp; governance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D, clinical \u0026amp; CMC drive costs — Phase 1 \u003cstrong\u003e$1–5M\u003c\/strong\u003e; Phase 2 \u003cstrong\u003e$10–40M\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D\/clinical and CMC dominate costs: Phase1 $1–5M, Phase2 $10–40M, CMC 20–30% pre‑IND with $1–10M scale‑up. Regulatory \u0026amp; safety ~$0.5–10M\/yr plus PDUFA $3.2M (2024). Commercial prep $10–50M; G\u0026amp;A ~20–25% of operating spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 Benchmark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003e$1–5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003ctd\u003e$10–40M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMC\u003c\/td\u003e\n\u003ctd\u003e20–30% pre‑IND; $1–10M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePDUFA\u003c\/td\u003e\n\u003ctd\u003e$3.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e20–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNet sales from approved small molecule therapies in oncology: as of 2024 ORIC Pharmaceuticals had no approved products and reported zero product revenue. Revenue potential would be driven by biomarker-eligible populations and line-of-therapy placement, concentrating value in targeted segments. Pricing strategy would reflect demonstrated clinical benefit balanced against competitive oncology pricing benchmarks. Geographic expansion into EU and APAC markets would add upside to future net sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestones from partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMilestone payments — upfronts (median ~$40M in 2024), staged development and regulatory fees, and commercial earn‑outs often structured to exceed $1B total — fund ORIC non‑dilutively while de‑risking programs. Payments are tied to key inflection points (IND, pivotal readouts, approval, sales) to align partner incentives and accelerate timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalties on partnered products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTiered royalties on net sales, commonly structured in the 5–20% range across industry licensing deals, provide ORIC with recurring revenue when partners commercialize candidates. These royalties can escalate with volume or new indications via step-ups tied to sales thresholds. Patent-protected products typically deliver 10+ years of post-approval cash flow, underpinning steady-state profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-promotion and profit share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-promotion and profit share gives ORIC shared commercialization economics in select territories (typically US and EU), enabling access to partner infrastructure while retaining upside through profit participation.\u003c\/p\u003e\n\u003cp\u003eSuccess requires closely aligned field execution and joint KPIs; when executed well, this model increases ORICs commercial leverage in major markets by reducing upfront investment and accelerating market access.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShared economics: partner-funded launch, retained upside\u003c\/li\u003e\n\u003cli\u003eInfrastructure: access to sales, distribution, regulatory teams\u003c\/li\u003e\n\u003cli\u003eExecution: aligned field teams and KPIs\u003c\/li\u003e\n\u003cli\u003eLeverage: faster scale in major markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D services and grants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-dilutive grants and research funding target resistance-focused projects, leveraging programs such as NIH SBIR\/STTR (Phase I up to $275,000; Phase II ~$1.75M in 2024) to fund early discovery without equity dilution. Occasional fee-for-service or platform-access contracts generate supplemental revenue and external validation from partners and CROs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNon-dilutive grants: NIH SBIR\/STTR Phase I $275,000; Phase II $1.75M (2024)\u003c\/li\u003e\n\u003cli\u003eFee-for-service\/platform access: variable, project-based\u003c\/li\u003e\n\u003cli\u003eBenefit: funds discovery, preserves equity, builds external validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZero 2024 rev; partner deals \u003cstrong\u003e$40M\u003c\/strong\u003e, royalties \u003cstrong\u003e5-20%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eORIC reported zero product revenue in 2024; future sales depend on biomarker-selected oncology indications and line placement with EU\/APAC expansion upside. Partner deals (median upfront ~$40M in 2024) plus staged milestones and tiered royalties (typical 5–20%) and selective co-promotion\/profit share provide de‑risked, recurring economics. Early R\u0026amp;D is supported by NIH SBIR\/STTR (Phase I $275,000; Phase II $1.75M) and fee‑for‑service.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRevenue Stream\u003c\/th\u003e\n\u003cth\u003e2024 Benchmark\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003eNo approvals in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront\/milestones\u003c\/td\u003e\n\u003ctd\u003eMedian ~$40M\u003c\/td\u003e\n\u003ctd\u003ePartner deals fund development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e5–20%\u003c\/td\u003e\n\u003ctd\u003eTiered, escalators common\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSBIR\/STTR\u003c\/td\u003e\n\u003ctd\u003ePhase I $275k; Phase II $1.75M\u003c\/td\u003e\n\u003ctd\u003eNon-dilutive R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098394464604,"sku":"oricpharma-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/oricpharma-business-model-canvas.png?v=1781802773","url":"https:\/\/pestel-analysis.com\/products\/oricpharma-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}